N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier

Drug Metabolism and Disposition

Volumn 38, Issue 6, 2010, Pages 917-922

  Kannan, Pavitra ^a,b   Brimacombe, Kyle R ^c   Zoghbi, Sami S ^a   Liow, Jeih San ^a   Morse, Cheryl ^a   Taku, Andrew K ^a   Pike, Victor W ^a   Halldin, Christer ^b   Innis, Robert B ^a   Gottesman, Michael M ^c   Hall, Matthew D ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CARBON 11; GLYCOPROTEIN P; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; N NORLOPERAMIDE; N NORLOPERAMIDE C 11; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

ANIMALS; ANTI-HIV AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CEREBROVASCULAR CIRCULATION; GLYCOPROTEINS; HUMANS; LOPERAMIDE; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

MUS;

EID: 77952318961     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.031161     Document Type: Article

References (31)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
2. Brimacombe KR, Hall MD, Auld DS, Inglese J, Austin CP, Gottesman MM, and Fung KL (2009) A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay Drug Dev Technol 7:233-249.
3. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, et al. (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115:3285-3290. (Pubitemid 41567593)
4. Clark JD, Balwin RL, Bayne KA, Brown MJ, Gebhart GF, Gonder JC, Gwathmey JK, Keeling ME, Kohn DF, Robb JW, Smith OA, Steggerda JA, and VandeBer JL (1996) Guide for the Care and Use of Laboratory Animals, National Academy Press, Washington, DC.
5. Fox E and Bates SE (2007) Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 7:447-459.
6. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615-627.
7. Gottesman MM, Fojo T, and Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58.
8. Graff CL and Pollack GM (2004) Drug transport at the blood-brain barrier and the choroid plexus. Curr Drug Metab 5:95-108.
9. Hendrikse NH, Schinkel AH, de Vries EG, Fluks E, Van der Graaf WT, Willemsen AT, Vaalburg W, and Franssen EJ (1998) Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124:1413-1418. (Pubitemid 28360563)
10. Henrich CJ, Robey RW, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, Dean M, and McMahon JB (2007) New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther 6:3271-3278.
11. Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, and Hall MD (2009) Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 86:368-377.
12. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, and Gottesman MM (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528. (Pubitemid 46175758)
13. 11C-N- desmethyl-loperamide. J Nucl Med doi: jnumed.109.070151v1.
14. Kurnik D, Sofowora GG, Donahue JP, Nair UB, Wilkinson GR, Wood AJ, and Muszkat M (2008) Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein. Anesthesiology 109:1092-1099.
15. 11C]verapamil. Epilepsia 48:1774-1784.
16. 11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem 51:6034-6043.
17. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, and Dey S (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601. (Pubitemid 28162914)
18. 11C-N-desmethyl-loperamide in monkeys. J Nucl Med 50:108-115.
19. Löscher W and Potschka H (2005a) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6:591-602. (Pubitemid 41059334)
20. Löscher W and Potschka H (2005b) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22-76. (Pubitemid 41033402)
21. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, and Callaghan R (1999) The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128:403-411. (Pubitemid 29458600)
22. Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, and Spiegel S (2006) Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci USA 103:16394-16399. (Pubitemid 44715207)
23. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, and Croop JM (1993) Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:977-984.
24. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, and Bates SE (2004) Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 64:1242-1246.
25. Schneider E, Horton JK, Yang CH, Nakagawa M, and Cowan KH (1994) Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54:152-158. (Pubitemid 24042102)
26. Shen DW, Cardarelli C, Hwang J, Cornwell M, Richert N, Ishii S, Pastan I, and Gottesman MM (1986) Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261:7762-7770. (Pubitemid 17208699)
27. Syvänen S, Lindhe O, Palner M, Kornum BR, Rahman O, Långström B, Knudsen GM, and Hammarlund-Udenaes M (2009) Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 37:635-643.
28. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234.
29. Vogelgesang S, Warzok RW, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer HK, Siegmund W, Walker LC, and Pahnke J (2004) The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 1:121-125.
30. Wu CP, Shukla S, Calcagno AM, Hall MD, Gottesman MM, and Ambudkar SV (2007) Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol Cancer Ther 6:3287-3296.
31. Zoghbi SS, Liow JS, Yasuno F, Hong J, Tuan E, Lazarova N, Gladding RL, Pike VW, and Innis RB (2008) 11C-Loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med 49:649-656. (Pubitemid 351520614)